Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS

Table 4

Matrix factor for atazanavir, darunavir, and ritonavir.

QC level	Atazanavir			Darunavir			Ritonavir
	Area response		Matrix factor; (B/A)	Area response		Matrix factor; (B/A)	Area response		Matrix factor; (B/A)
	A	B		A	B		A	B
LQC	10061	9773	0.97	19583	20074	1.03	6137	6074	0.99
MQC-2	103108	104201	1.01	189378	183148	0.97	63019	64148	1.02
MQC-1	1694608	1654728	0.98	2487277	2491752	1.00	404237	390617	0.97
HQC	3408890	3382518	0.99	5047023	4922563	0.98	846102	821547	0.97
QC level	Atazanavir-d6			Darunavir-d9			Ritonavir-d6
	Area response		Matrix factor; (B/A)	Area response		Matrix factor; (B/A)	Area response		Matrix factor; (B/A)
	A	B		A	B		A	B
LQC	347253	338514	0.97	531482	530681	1.00	103941	105065	1.01
MQC-2	344253	348240	1.01	523378	510151	0.97	104106	102738	0.99
MQC-1	346748	341729	0.99	534156	541747	1.01	100574	98827	0.98
HQC	340675	331508	0.97	532074	520571	0.98	100078	97538	0.97

LQC: low quality control; MQC: medium quality control; HQC: high quality control.
A: mean area response of six replicate samples prepared in mobile phase (neat samples).
B: mean area response of six replicate samples prepared by spiking in extracted blank plasma.